Change of Principal Investigator for Monepantel Pet Dog Lymphoma Phase IIb Trial

- Ex-Elanco, Merial and Boehringer-Ingelheim executive Dr Kim Agnew commences as Principal Investigator of ongoing pet dog lymphoma clinical trial

14 May 2021 – Perth, Australia: PharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has appointed Dr Kim Agnew BSc (Hons) BVSc MACVSc as the new Principal Investigator for PharmAust's Phase IIb Veterinary Clinical Trial testing monepantel in pet dogs with treatment naïve B cell lymphoma.

The trial is entitled "The use of the anthelminthic drug monepantel as an anticancer drug in dogs" and is being run across five sites in Perth, Sydney and Brisbane.

Dr Agnew brings 25 years of experience in the animal health industry in business development, product development, regulatory affairs, clinical research, technical support and pharmacovigilance to the trial. Dr Agnew's experience includes positions at:

- Boehringer-Ingelheim as ANZ Research and Development Leader (four years)
- Merial as Research and Development Leader Oceania and Consultant (two years)
- Elanco, Research and Regulatory Manager, Innovation Manager and Associate Director of Research and Development (18 years).

Dr Kim Agnew stated, "I am very excited to be able to join the PharmAust team and the very experienced canine oncologists in contributing to such an important set of studies. Canine lymphoma is a devastating disease for dogs and owners and I am sure that, given the team involved in these studies, the best possible data outcomes will be achieved."

PharmAust's Chief Scientific Officer, Dr Richard Mollard stated, "PharmAust is delighted to have the opportunity to work with Dr Agnew in this setting. Dr Agnew is an ideally qualified appointment and PharmAust looks forward to benefiting from his broad experience in industry settings. Unfortunately, this change also means that accruals will cease at the Melbourne site. However, recruitment at other sites continues at pace and we do not foresee a change in the overall timing of deliverables."

PharmAust thanks Dr Claire Cannon of University of Melbourne, U-Vet Animal Hospital, for her work as Principal Investigator overseeing this clinical trial for the past two years. Dr Cannon is commencing a new private sector veterinary services career position. Dr Cannon has provided an invaluable service to PharmAust and its shareholders with trial design and adjudicating trial accruals and outcomes of the individual trial participants.

This announcement is authorised by the Board

Enquiries:

Dr Roger Aston
Executive Chairman and CEO
Tel: 0402 762 204
rogeraston@pharmaust.com

Dr Richard Mollard
Chief Scientific Officer
Tel: 0418 367 855
rmollard@pharmaust.com

About PharmAust (PAA):
PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated $3.5 million in revenue in FY 2020.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth, neurodegenerative diseases and viral infections. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative and antiviral disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.